Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4443112 | 0.88 | LMNA (0.55) | ESR2GLALMNAESR1PGR | |
| SCHEMBL1790363 | 0.84 | LMNA (0.52) | GLALMNAESR1PGRCHRM2 | |
| SCHEMBL28935806 | 0.83 | ESR2 (0.56) | ESR2HRH3PDE4APDE4BPDE4C | |
| SCHEMBL1790802 | 0.83 | MAPT (0.50) | GLALMNAHRH3ESR1PGR | |
| SCHEMBL20603030 | 0.81 | ESR2 (0.45) | ESR2GLALMNAESR1PGR | |
| SCHEMBL20620789 | 0.81 | ESR2 (0.45) | ESR2GLALMNAESR1PGR | |
| SCHEMBL4359622 | 0.81 | CYP3A4 (0.49) | ESR2LMNAHSD17B10PDE4APDE4B | |
| SCHEMBL14877967 | 0.81 | ESR2 (0.55) | ESR2GLALMNAESR1PGR | |
| SCHEMBL14950767 | 0.80 | MAPT (0.50) | GLALMNAESR1PGRCHRM2 | |
| SCHEMBL27868171 | 0.79 | ESR2 (0.47) | ESR2HRH3POLBPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12139470-B2 | Trioxolane agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-12 | — | — | US | disclosed |
| US-20220411396-A1 | TRIOXOLANE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-12-29 | — | — | US | disclosed |
| US-20220411396-A1 | TRIOXOLANE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-12-29 | — | — | US | disclosed |
| US-11072594-B2 | Trioxolane agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-27 | — | — | US | disclosed |
| US-11072594-B2 | Trioxolane agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200140406-A1 | TRIOXOLANE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-05-07 | — | — | US | disclosed |
| US-20200140406-A1 | TRIOXOLANE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-05-07 | — | — | US | disclosed |
| WO-2019005977-A1 | TRIOXOLANE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2009091433-A2 | SPIRO AND DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2009-07-23 | — | — | WO | disclosed |
| US-6825230-B2 | PEROXY COMPOUNDS SUCH AS ADAMANTANE-2-SPIRO-3'-8'-((1'S)-10'-CAMPHORSULFONYL)-1',2',4'-TRIOXA-8' -AZASPIRO(4.5) DECANE, USED FOR PROPHYLAXIS OF MALARIA OR SCHISTOSOMIASIS INFECTIONS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2004-11-30 | — | — | US | disclosed |
| US-20040039008-A1 | Spiro and dispiro 1,2,4-trioxolane antimalarials | MEDICINES FOR MALARIA VENTURES MMV (CH) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411396-A1 | TRIOXOLANE AGENTS | ABCB4, SLC10A1, SLC10A2 | ESR2 640/4885GLA 1326/4885LMNA 1059/4885 |
| US-11072594-B2 | Trioxolane agents | ABCB4, SLC10A1, SLC10A2 | ESR2 640/4885GLA 1326/4885LMNA 1059/4885 |
| US-20200140406-A1 | TRIOXOLANE AGENTS | ABCB4, SLC10A1, SLC10A2 | ESR2 640/4885GLA 1326/4885LMNA 1059/4885 |
| US-12139470-B2 | Trioxolane agents | ABCB4, SLC10A1, SLC10A2 | ESR2 640/4885GLA 1326/4885LMNA 1059/4885 |
| US-20040039008-A1 | Spiro and dispiro 1,2,4-trioxolane antimalarials | DHODH, THPO, SQLE | ESR2 1687/4885GLA 4215/4885LMNA 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.